1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Autor:	C. Utt, Z. Zhang, D. Wilson, S.S. Schalm, M. Dorsch, Byoung Chul Cho, J. Campbell, Chae Won Park, C. de Savi, M. Eno, F. Stevison, K. Hoeflich, K. Wilson, T. Dineen, B. Williams, R. Woessner, T. Guzi, Sun Min Lim, J. Hsieh
Rok vydání:	2020
Předmět:	Egfr tki Oncology business.industry Cancer research Medicine EGFR T790M Hematology business
Zdroj:	Annals of Oncology. 31:S839
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::530581c491464df151bf2102012f1266 https://doi.org/10.1016/j.annonc.2020.08.1610 Zobrazit plný text záznamu